Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.65 |
| ▸ | HTR2A | P28223 | 1/20 | 0.65 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.62 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | HTR7 | P34969 | 1/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7232114 | 0.87 | HTR2C (0.64) | HTR2CHTR2AMTNR1AMTNR1BMAPT | |
| SCHEMBL21335673 | 0.84 | HTR2A (0.48) | HTR2CHTR2AMTNR1AMTNR1BMAPT | |
| SCHEMBL4394702 | 0.84 | MTNR1A (0.48) | HTR2CHTR2AMTNR1AMTNR1BMAPT | |
| Dimethylamine SCHEMBL3332584 | 0.83 | MTNR1A (0.60) | HTR2CHTR2AMTNR1AMTNR1BMAPT | |
| SCHEMBL22946242 | 0.81 | HTR2C (0.68) | HTR2CHTR2AMTNR1AMTNR1BMAPT | |
| SCHEMBL12386902 | 0.81 | HTR2C (0.57) | HTR2CHTR2AMTNR1AMTNR1BMAPT | |
| SCHEMBL980725 | 0.80 | MTNR1A (0.47) | HTR2CHTR2AMTNR1AMTNR1BMAPT | |
| SCHEMBL11984620 | 0.80 | MTNR1A (0.63) | HTR2CHTR2AMTNR1AMTNR1BMAPT | |
| SCHEMBL23927832 | 0.79 | HTR2A (1.00) | HTR2CHTR2AMTNR1AMTNR1BHTR7 | |
| SCHEMBL7997598 | 0.79 | HTR2C (0.81) | HTR2CHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3298003-B1 | BENZOIMIDAZOLE DERIVATIVES AS PAD4 INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2023-04-19 | — | — | EP | disclosed |
| US-10815218-B2 | Benzoimidazole derivatives as PAD4 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-10-27 | — | — | US | disclosed |
| US-10407407-B2 | Benzoimidazole derivatives as PAD4 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-09-10 | — | — | US | disclosed |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-8013006-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013006-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-7973069-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20070299069-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070299069-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070299069-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
| WO-2007084413-A2 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007084435-A2 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007084435-A2 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| EP-1771169-A1 | METHODS FOR TREATING HEPATITIS C | PTC Therapeutics, Inc. (US) | 2007-04-11 | — | — | EP | disclosed |
| US-20060223863-A1 | Methods for treating Hepatitis C | KARP GARY M | 2006-10-05 | — | — | US | disclosed |
| US-20060189606-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2006-08-24 | — | — | US | disclosed |
| WO-2006019831-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407407-B2 | Benzoimidazole derivatives as PAD4 inhibitors | PADI4, PADI1, PADI2 | HTR2C 4706/4885HTR2A 4841/4885MTNR1A 4679/4885 |
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, LIPC, HCCS | HTR2C 2510/4885HTR2A 3904/4885MTNR1A 1243/4885 |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | HTR2C 3217/4885HTR2A 3927/4885MTNR1A 555/4885 |
| US-20060189606-A1 | Methods for treating hepatitis C | HAVCR2, EIF2AK2, MAVS | HTR2C 4031/4885HTR2A 4616/4885MTNR1A 2303/4885 |
| US-20070299069-A1 | Methods for treating hepatitis C | HAVCR2, EIF2AK2, MAVS | HTR2C 4031/4885HTR2A 4616/4885MTNR1A 2303/4885 |
| US-20060223863-A1 | Methods for treating Hepatitis C | OAT, HAVCR2, HCCS | HTR2C 3217/4885HTR2A 3927/4885MTNR1A 555/4885 |
| US-10815218-B2 | Benzoimidazole derivatives as PAD4 inhibitors | PADI4, PADI1, PADI2 | HTR2C 4706/4885HTR2A 4841/4885MTNR1A 4679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.